- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01952795
Effect of Hypocaloric Diet and Exercise in Obese Women Who Are Subjected to IVF Cycle
August 21, 2017 updated by: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
The purpose of this study is to determine the impact of diet and physical exercise program on pregnancy rate and live birth in obese women who undergo an IVF cycle.
Study Overview
Detailed Description
The objective of this study is showing that obesity significantly affects the in vitro fertilization cycles lowering the reproductive capacity.
The study is been performed in Hospital de la Santa Creu i Sant Pau and Fundació Puigvert of Barcelona.
Patients recluted are obese women with sterility problems that require in vitro fertilization (IVF) with a body mass index BMI between 30-35.
It´s a randomised study in which half of the patients undergo to a 6 weeks program of diet and exercice.
We will analyse the response to ovaric stimulation, the results of the egg retrieval (ovocyte number and quality), rates of fecundation, embryo implantation and clinical gestation.
Study Type
Interventional
Enrollment (Actual)
41
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Barcelona, Spain, 08025
- Hospital de la Santa Creu i Sant Pau
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women who want pregnancy.
- Basal FSH levels ≤ 10 IU / l.
- Infertility to justify treatment with IVF/ICSI.
- Being included in a long protocol with GnRH agonist.
- Presence of both ovaries and uterus able to support embryo implantation and pregnancy.
- Body mass index (BMI) ≥ 30 kg/m2 and ≤ 35 kg/m2.
- Absence of pregnancy before starting ovarian stimulation.
- Having given their written consent.
Exclusion Criteria:
- Female age ≤ 18 years and ≥ 35 years.
- Severe male factor not permit an IVF-ICSI with ejaculated sample.
- Patients with low ovarian reserve (basal FSH levels ≥ 10 IU / l or lower antral follicle count to 6 follicles in both ovaries).
- HIV seropositivity, HBV or HCV.
- Clinically important disease.
- Having frozen embryos from previous cycles of assisted reproduction.
- Unexplained vaginal bleeding.
- Poor response in previous IVF cycles with standard stimulation protocols
- Any contraindication to become pregnant.
- Known allergy to preparations of gonadotropins or its excipients.
- High consumption of alcohol, drugs or psychotropic drugs.
- Concurrent participation in another study.
- Patients who have done previous cycles of IVF / ICSI without success
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Diet and exercise
Total caloric intake aimed at maintaining a diet with> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day. 3 sessions per week on a bicycle ergometer or on a treadmill (according to body fat distribution and other parameters) modifications carried out weekly, with a gradual increase as to exercise until maximal oxygen consumption 60 - 70% would always preceded by heating 5 minutes.
|
Total caloric intake aimed at maintaining a diet with> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day.
|
|
No Intervention: No intervention
Usual diet and exercise
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pregnancy rate
Time Frame: 14 days after embryo transfer
|
Pregnancy rate by cycle
|
14 days after embryo transfer
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hyperstimulation rate
Time Frame: At luteal phase and first weeks of pregnancy
|
Number of patients with moderate or severe hyperstimulation
|
At luteal phase and first weeks of pregnancy
|
|
Fertility rate
Time Frame: 24 hours post pick up
|
Rate of mature oocytes fertilized by conventional IVF or ICSI
|
24 hours post pick up
|
|
Mature oocytes
Time Frame: Pick up day
|
Number of total mature oocytes obtained after stimulation
|
Pick up day
|
|
Cancellation rate
Time Frame: Durinf the stimulation in follicular phase
|
Stimulated Patients who fail to perform the follicular puncture
|
Durinf the stimulation in follicular phase
|
|
Good quality embryos
Time Frame: Day 3 to 5 post pick up
|
Number of good quality embryos obtained (A and B) by patient
|
Day 3 to 5 post pick up
|
|
Abortion rate
Time Frame: First trimester of pregnancy
|
Number of non evolutive pregnancies during the first trimester
|
First trimester of pregnancy
|
|
Live birth rate
Time Frame: Between 7 a 9 months after treatment
|
Amount of patients who finish the treatment with a live newborn
|
Between 7 a 9 months after treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Leptin, adiponectin, resistin, interleukin VI, TNF-α, visfatin, IGF1 and PAI I
Time Frame: During the stimulation phase
|
Study the relationship between obesity and measurable surrogate parameters the same as the products of secretion of fat (leptin, adiponectin, resistin, interleukin VI, TNF-α, visfatin, IGF1 and PAI I) or with inflammatory parameters results of an IVF cycle.
|
During the stimulation phase
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Juan José Espinós-Gómez, MD, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Actual)
December 1, 2015
Study Completion (Actual)
April 1, 2016
Study Registration Dates
First Submitted
September 23, 2013
First Submitted That Met QC Criteria
September 25, 2013
First Posted (Estimate)
September 30, 2013
Study Record Updates
Last Update Posted (Actual)
August 22, 2017
Last Update Submitted That Met QC Criteria
August 21, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- IIBSP-DHE-2011-42
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
Clinical Trials on Diet and exercise
-
Göteborg UniversityThe Swedish Research Council; Swedish Council for Working Life and Social ResearchCompleted
-
Florida International UniversityTerminatedDiabetes | Frailty | Senior SyndromeUnited States
-
Rabin Medical CenterSoroka University Medical Center; D-Cure, IsraelCompleted
-
University of PittsburghUniversity of PennsylvaniaCompleted
-
USDA Grand Forks Human Nutrition Research CenterWithdrawn
-
Changi General HospitalCompletedQuality of Life | Inflammation | Sexual Dysfunction | Endothelial DysfunctionSingapore
-
Universidade Católica PortuguesaAssociação para o Desenvolvimento do Centro Académico de Investigação e Formação...Active, not recruitingCardiovascular Disease RiskPortugal
-
American Scitech InternationalProactive Clinical ResearchUnknownType II Diabetes MellitusUnited States, India
-
University of AlexandriaCompleted
-
Dana-Farber Cancer InstitutePatient-Centered Outcomes Research InstituteRecruitingCancer SurvivorshipUnited States